Price
$2.08-49.88%Social Signal Score
Analyst Ratings
3 analystsRevenue
$7.87MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Zaki Rakib
- Sector
- Industrials
- Industry
- Agricultural - Commodities/Milling
- Employees
- 89
- Beta
- 1.31
- Country
- CA
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -3.16
Financials
Revenue
$7.87M+18631.0%Net Income
$-3.32MEBITDA
$-2.44MFree Cash Flow
$-2.91MEPS (diluted)
$-0.15Shares Outstanding (diluted)
22.67M+5202.6%Operating Expenses
$7.28MCash & Debt
$12.49MRevenue by Segment (annual)
$67.14MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $34.51M | $-11.13M | $-0.60 |
| 2024 | $25.19M | $-12.91M | $-0.80 |
| 2023 | $12.67M | $-12.56M | $-0.93 |
| 2022 | $5.50M | $-11.24M | $-0.70 |
| 2021 | $2.10M | $-9.83M | $-0.70 |
| 2020 | $396.0K | $-6.58M | $-0.70 |
| 2019 | $218.0K | $-5.31M | $-1.75 |
| 2018 | $0.00 | $0.00 | $-2.34 |
| 2017 | $0.00 | $-5.0K | $-0.21 |
| 2016 | $0.00 | $-103.4K | $-0.27 |
| 2015 | $0.00 | $-123.7K | $-0.31 |
| 2014 | $0.00 | $0.00 | $-0.72 |
| 2013 | $0.00 | $0.00 | $-1.17 |
Valuation
BHSThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
30-80.00%Social Signal Score
Mentions (15)
- Newszacks.com·10d ago·Negative
BioHarvest Sciences Inc. (BHST) Reports Q3 Loss, Misses Revenue Estimates BioHarvest Sciences Inc. (BHST) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.14 per share a year ago.
View source ↗ - Newsnewsfilecorp.com·24d ago·Neutral
… 2026 Financial Results on November 12, 2026 Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - October 29, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (TASE: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that it will report its third quarter 2026 financial results before the market opening on Thursday, November 12, 2026. The Company will host a conference call an…
View source ↗ - Newsproactiveinvestors.com·40d ago·Neutral
BioHarvest takes second plant-cell asset to commercial readiness BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said on Tuesday that Olive Cell, an olive-derived plant-cell ingredient, is ready for commercial licensing, the second product from its Botanical Synthesis technology to reach that stage. The company said Olive Cell has completed large-scale bioreactor scale-up, manufacturing readiness and a self-affirmed U.S. Generally Recognized as Safe (GRAS) process.
View source ↗ - Newsnewsfilecorp.com·45d ago·Negative
…. - October 8, 2026) - Tate & Lyle PLC (Tate & Lyle), a global leader in ingredient solutions for healthier food and beverages, and BioHarvest Sciences Inc. (NASDAQ: BHST) (TASE: BHST) (BioHarvest), today announced an important milestone in their next-generation sweetener development programme. The programme has demonstrated that BioHarvest's Botanical Synthesis™ platform is capable of producing the targeted next-generation sweetening solution.
View source ↗ - Newsnewsfilecorp.com·54d ago·Negative
…ciences Announces Share Repurchase Program Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - September 29, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (TASE: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a Botanical Synthesis company developing and manufacturing proprietary plant-based compositions for customers, partners and its own portfolio, announced today that its Board of Directors has authorized a share repurchase program, structured in accordance with Canadian p…
View source ↗ - Newsnewsfilecorp.com·68d ago·Neutral
…itions to differentiated consumer products Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - September 15, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (TASE: BHST) (FSE: 8MV0), a Botanical Synthesis company developing and manufacturing proprietary plant-based compositions for customers and its own portfolio, today announced the launch of single-dose VINIA® Daily Chews. The new delivery format is designed to expand the addressable market for VINIA and to further demonstrate B…
View source ↗ - Newsproactiveinvestors.com·79d ago·Neutral
Fiinu shares jump over 6% as Conister Bank platform enters production Fiinu (AIM: BANK), the UK fintech group, rose over 6% to 4p on Friday after its Plugin Overdraft platform moved into production ahead of a planned year-end...
View source ↗ - Newsproactiveinvestors.com·80d ago·Neutral
BioHarvest Sciences plans Tel Aviv Stock Exchange dual listing BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) plans to pursue a dual listing of its ordinary shares on the Tel Aviv Stock Exchange (TASE), with trading expected to begin on September 8, 2026. The company, which is listed on the Nasdaq Capital Market, expects the TASE listing to provide investors in Israel with access to its shares.
View source ↗ - Newsnewsfilecorp.com·80d ago·Neutral
…sting on the Tel Aviv Stock Exchange (TASE) Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - September 3, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development today announced its intention to offer its ordinary shares on the Tel Aviv Stock Exchange (TASE) and to become dual-listed for trade on both the Nasdaq and TASE markets. BioHarvest expects its shares to begin trading on the…
View source ↗ - Newsseekingalpha.com·103d ago·Positive
BioHarvest Sciences Inc. (BHST) Q2 2026 Earnings Call Transcript BioHarvest Sciences Inc. (BHST) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·103d ago·Neutral
BioHarvest Sciences Q2 Earnings Call Highlights BioHarvest Sciences NASDAQ: BHST reported second-quarter 2026 revenue of $8.8 million, up 3.8% from $8.5 million a year earlier, while highlighting its first manufacturing and supply agreement within its contract development and manufacturing organization, or CDMO, business.
View source ↗ - Newsproactiveinvestors.com·103d ago·Neutral
BioHarvest posts higher Q2 revenue, secures manufacturing deal for premium fragrance compound BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) reported higher second-quarter revenue as the plant-based molecule developer shifted spending toward manufacturing capacity. Revenue for the quarter was $8.8 million, up 3.8% from a year earlier.
View source ↗ - Newszacks.com·103d ago·Negative
BioHarvest Sciences Inc. (BHST) Reports Q2 Loss, Lags Revenue Estimates BioHarvest Sciences Inc. (BHST) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.15 per share a year ago.
View source ↗ - Newsnewsfilecorp.com·103d ago·Negative
BioHarvest Reports Second Quarter 2026 Financial Results and Provides Business Update Secured first ever CDMO Manufacturing Agreement supporting planned 20-ton commercial production program over two years for rare botanical fragrance, that BioHarvest expects to drive profitable growth trajectory for CDMO business Reports $8.8 million in Q2 revenue, up 3.8% from Q2 2025 Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - August 11, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (FS
View source ↗ - Newsnewsfilecorp.com·103d ago·Negative
BioHarvest Secures 20-Ton Manufacturing and Supply Agreement for Rare Botanical Luxury Fragrance Exclusive agreement through 2027 and 2028 is estimated to generate $20-$30 million in revenue Positions BioHarvest in sustainable rare luxury fragrance manufacturing BioHarvest to target additional collaborations in the high-margin rare fragrance space Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - August 11, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (FSE: 8MV0), a leader in
View source ↗
Earnings
Tue, Mar 30(in 4 months)
Consensus estimate $-0.18 per share
Typical surprise +2.4% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 12$-0.15 vs $-0.16beat
- Tue, Aug 11$-0.17 vs $-0.13miss
- Thu, May 14$-0.11 vs $-0.13beat
- Tue, Mar 31$-0.10 vs $-0.10beat
- Thu, Nov 13$-0.14 vs $-0.14beat
- Mon, Aug 11$-0.24 vs $-0.11miss
Estimates and results for BHST via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in BHST.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
